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ABSTRACT 
Background In cystic fibrosis and bronchiectasis, 
genetic mannose binding lectin (MBL) deficiency is 
associated with increased exacerbations and earlier 
mortality; associations in COPD are less clear. Preclinical 
data suggest MBL interferes with phagocytosis of 
Haemophilus influenzae, a key COPD pathogen. We 
investigated whether MBL deficiency impacted on clinical 
outcomes or microbiota composition in COPD.
Methods Patients with COPD (n=1796) underwent 
MBL genotyping; linkage to health records identified 
exacerbations, lung function decline and mortality. A 
nested subcohort of 141 patients, followed for up to 
6 months, was studied to test if MBL deficiency was 
associated with altered sputum microbiota, through 
16S rRNA PCR and sequencing, or airway inflammation 
during stable and exacerbated COPD.
Findings Patients with MBL deficiency with COPD 
were significantly less likely to have severe exacerbations 
(incidence rate ratio (IRR) 0.66, 95% CI 0.48 to 0.90, 
p=0.009), or to have moderate or severe exacerbations 
(IRR 0.77, 95% CI 0.60 to 0.99, p=0.047). MBL deficiency 
did not affect rate of FEV1 decline or mortality. In the 
subcohort, patients with MBL deficiency had a more diverse 
lung microbiota (p=0.008), and were less likely to be 
colonised with Haemophilus spp. There were lower levels of 
airway inflammation in patients with MBL deficiency.
Interpretation Patients with MBL deficient genotype 
with COPD have a lower risk of exacerbations and a 
more diverse lung microbiota. This is the first study to 
identify a genetic association with the lung microbiota 
in COPD.
InTRoduCTIon
Chronic obstructive pulmonary disease (COPD) is 
characterised by airway inflammation, with periods 
of symptom exacerbation, leading to irreversible 
airflow limitation, lung damage and mucus hyper-
secretion. COPD has multiple phenotypes and an 
unpredictable clinical course.1 Culture indepen-
dent techniques have shown that lungs of healthy 
adults and patients with COPD harbour a diverse 
microbiota.2 It is likely that genetic influences affect 
disease outcomes and microbiota composition 
through modulation of host defence mechanisms. 
There are few studies of genetic modifiers of exac-
erbation risk in COPD, and no studies relating host 
genotype with lung microbiota.3 4  
Mannose binding lectin (MBL), an innate immune 
system component, activates the lectin complement 
pathway and opsonises organisms for phagocytosis; 
it accumulates in the lungs during inflammation.5 
Individuals with specific single nucleotide poly-
morphisms (SNPs) of the MBL2 gene cannot form 
stable multimeric forms, leading to systemic defi-
ciency of the MBL protein.6 Of the population, 
10%–30% carry MBL deficient haplotypes but 
have no detectable phenotype when healthy.7 In 
populations with bronchiectasis or cystic fibrosis 
(CF), MBL deficiency is associated with more 
exacerbations (including severe exacerbations), 
faster decline in FEV1, and increased Pseudomonas 
aeruginosa colonisation.7 8 In COPD, associations 
between MBL deficiency and hospitalisations for 
acute exacerbations or more frequent exacerba-
tions have been identified,9 10 whereas Eagan et 
al11 found no relationship between MBL plasma 
levels and COPD risk or disease severity. It could 
be assumed that MBL deficiency in COPD, CF or 
bronchiectasis would have similar effects but there 
are clear differences in the inflammatory profiles 
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Key messages
What is the key question?
 ► COPD is a heterogeneous disease with 
airway inflammation being driven by 
bacterial infections, yet no studies to date 
have examined microbiology or infection 
risk in COPD in relation to mannose binding 
lectin (MBL) genotype.
What is the bottom line?
 ► We identified that genetic MBL deficiency was 
protective against exacerbation risk in a large 
population of patients with COPD. We explored 
the mechanism of this effect and identified that 
MBL deficiency was associated with reduced 
presence of Haemophilus spp in the airway 
microbiota.
Why read on?
 ► This is one of the largest studies of the COPD 
lung microbiota to date, and is the first study 
to demonstrate that MBL deficiency is a key 
contributor to infection risk in COPD.
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Chronic obstructive pulmonary disease
and microbiota of these diseases. MBL undergoes oxidation in 
the COPD airway; oxidised MBL suppresses macrophage phago-
cytosis of Haemophilus influenzae, a key COPD pathogen.12 
Failed macrophage phagocytosis in COPD has been extensively 
described and is likely to contribute to exacerbation risk.13 
Paradoxically, MBL deficiency could be beneficial in COPD, by 
removing a key inhibitor of macrophage function and bacterial 
clearance. This study was designed to test if MBL deficiency 
protects against exacerbations and is associated with a lower 
abundance of Haemophilus spp in the COPD airway.
MeThodS
Tayside Allergy and Respiratory disease Information System  
population based genetic study
In 2008, patients age >40 years; with an FEV1/FVC 
ratio <70% and a clinical diagnosis of COPD were invited to 
participate in a primary care based longitudinal cohort study 
and population registry called Tayside Allergy and Respira-
tory Disease Information System (TARDIS). Patients were 
reviewed annually for lung function performance, recording 
of symptoms and exacerbation history. The inclusion criteria 
were age >40 years, a postbronchodilator FEV1/FVC ratio 
of <70% and a clinical diagnosis of COPD. Record linkage was 
used to obtain prescribing history, hospitalisations, morbidity 
and death, using the Scottish morbidity database, the Tayside 
community prescription database and the General Register 
Office for Scotland. Patients gave informed consent to partic-
ipate . Saliva was collected for DNA extraction using Oragene 
kits (DNA Genotek). In the present analysis we excluded 
patients with a primary diagnosis of bronchiectasis, asthma or 
immunodeficiency.
SnP genotyping
TARDIS DNA samples were genotyped for four MBL2 
SNPs (promoter region SNP rs7096206, and exon 1 SNPs 
rs1800450, rs1800451, rs5030737) which previous studies 
have used to define genetic MBL deficiency.6 Further details 
of SNP genotyping are shown in the online supplementary 
material . Patients were classified as deficient, intermediate 
or sufficient MBL genotype according to generally accepted 
definitions.6
TARdIS outcomes
The primary outcome was to determine if MBL deficiency 
was associated with frequency of exacerbations. Exacerbations 
were recorded annually and validated against prescribing and 
hospital admission data. Local guidelines for COPD exacerba-
tion management recommend 30–40 mg/day prednisolone with 
antibiotics prescribed in the presence of purulent sputum. Exac-
erbations were identified as an acute prescription for >20 mg/
day of prednisolone (moderate exacerbations) and/or admission 
to hospital due to exacerbation of COPD (severe exacerbation). 
Prescribing data were used to distinguish between those exacer-
bations treated with corticosteroids alone or those also treated 
with antibiotics. Statistical models were constructed comparing 
MBL sufficient, intermediate and deficient genotypes (three level 
model) and comparing MBL deficient to non-deficient (inter-
mediate and sufficient combined) genotypes (two level model). 
Secondary outcomes investigated were decline in FEV1 over 
time, admissions to hospital for cardiovascular events (including 
myocardial infarction, cardiac failure and arrhythmias) and 
all-cause, respiratory or cardiovascular mortalities.
Microbiota subcohort study
Subsequently, a nested cohort of patients was recruited, based on 
MBL genotype, into a more detailed study to identify the impact 
of MBL deficiency on exacerbation risk. Patients with known 
MBL genotype, who were alive in 2013 and had given consent 
to be contacted again for research studies were approached by 
letter. Those that responded to the invitation were screened and 
included in the subcohort study.
Patients enrolled during a period of disease stability were 
followed up for between 3 months to 6 months. During this 
period, patients contacted the study team in the event of an 
exacerbation as defined in the online supplementary material.14 
Blood and sputum samples for analysis of systemic and airway 
inflammation, and for examination of lung microbiota, were 
taken at the beginning and end of the study (when clinically 
stable) and at the beginning and 10 days after the start of exac-
erbations. Inclusion and exclusion criteria and study procedures 
are shown in the online supplementary material.
Systemic and airway inflammation
Sputum and serum biomarkers (interleukin (IL) 1β, IL-8 and 
tumour necrosis factor α (TNFα), extracellular newly iden-
tified receptor for advanced glycation end products binding 
protein (EN-RAGE), myeloperoxidase, C-reactive protein (CRP), 
CD40L, P-selectin) were measured by ELISA as described in the 
online supplementary material.
Sputum microbiota
DNA extracted from whole sputum underwent PCR and 
sequencing of the bacterial 16S rRNA gene on the Illumina 
MiSeq followed by bioinformatic analysis in the Quantitative 
Insights Into Microbial Ecology pipeline V.1.9.0 as described in 
the online supplementary material.
Bacterial binding studies
The ability of MBL and the closely related molecules ficolins 2 
and 3 to bind to clinically relevant respiratory pathogens were 
assessed in vitro as detailed in the online supplementary material.
Statistical analysis
Descriptive data are expressed as mean ±SD or count with 
percentage as appropriate. Sample size was empirical based on 
the number of available patients within the TARDIS cohort. 
Exacerbation frequency was evaluated using negative binomial 
models accounting for differing lengths of follow-up per patient. 
Survival was assessed by Cox proportional hazards regression 
from date of enrolment to death. Comparison of the average 
annual rate in decline of FEV1 between MBL deficient, interme-
diate and sufficient patients was performed using multiple linear 
regression. The annualised rate of FEV1 decline was determined 
from the difference between the FEV1 recorded at the final 
TARDIS visit and the baseline visit divided by follow-up time. 
Multivariable models were adjusted for gender, Deprivation 
Index, prescriptions for inhaled corticosteroids (ICS), broncho-
dilators and other medications (listed in table 1), smoking status 
and pack years, FEV1, post bronchodilator FEV1, comorbidities 
of cardiovascular disease, liver disease, renal disease, hyperten-
sion and diabetes. Data were obtained from record linkage and 
so no missing data were encountered for prescribing, morbidity 
and mortality data. Subgroups were predefined including 
examining exacerbations requiring corticosteroids versus those 
requiring antibiotics, and moderate versus severe exacerbations 
(defined as those requiring hospital admission). All models used 
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Table 1 Table showing the baseline characteristics of the Tayside 
Allergy and Respiratory Disease Information System (TARDIS) cohort 
analysis by mannose binding lectin (MBL) genotype. p Values were 
calculated by three-way comparisons (Kruskal-Wallis for non-
parametrical data, analysis of variance for parametrical data and Χ2 
test for categorical data) across all groups
MBL deficient 
genotype
MBL 
intermediate 
genotype
MBL 
sufficient 
genotype p Value
N (% of study cohort) 240 (13.4) 586 (32.6) 970 (54.0) n/a
Average follow-up 
length in years (SD)
5.44 (±2.1) 5.34 (±2.0) 5.43 (±2.1) 0.9
Age at 
diagnosis, years (SD)
65.6 (±9.0) 64.23 (±9.6) 64.4 (±9.6) 0.1
Male gender (% of 
group)
131 (54.6) 308 (52.7) 506 (52.2) 0.8
Cigarette smoking by 
pack years (SD)
41.6 (±20.6) 41.0 (±20.3) 41.3 (±22.7) 0.7
Body mass index (SD) 27.0 (±5.6) 26.9 (±5.4) 27.2 (±5.6) 0.9
FEV1 % predicted (SD) 79.6 (±20.8) 78.7 (±24.4) 78.0 (±22.1) 0.3
MRC Dyspnoea Score 
(SD)
2.44 (±1.0) 2.53 (±1.0) 2.48 (±1.0) 0.6
FEV1/FVC (SD) 0.59 (±0.1) 0.58 (±0.1) 0.58 (±0.1) 0.3
Comorbidities
Cardiovascular 
disease (% of group)
24 (10.0) 53 (9.0) 78 (8.0) 0.6
Renal failure (% of 
group)
5 (2.1) 17 (2.9) 19 (2.0) 0.5
Cancer (% of group) 12 (5.0) 29 (4.9) 39 (4.0) 0.6
Hypertension (% of 
group)
137 (57.1) 322 (54.9) 524 (54.0) 0.7
Diabetes (% of group) 48 (20.0) 105 (17.9) 194 (20.0) 0.6
Therapies
Inhaled corticosteroids 
(% of group)
123 (51.3) 349 (59.6) 570 (58.8) 0.1
Long-acting 
muscarinic antagonist 
(% of group)
67 (27.9) 175 (29.9) 257 (26.5) 0.4
Statins (% of group) 71 (29.6) 178 (30.4) 313 (32.3) 0.6
Figure 1 Flow chart of samples through the Tayside Allergy and 
Respiratory Disease Information System (TARDIS) and microbiome 
subcohort studies. MBL, mannose binding lectin.
Chronic obstructive pulmonary disease
time-dependent analysis to account for changes in these vari-
ables over the course of follow-up. Differences between effect 
estimates were compared using interaction testing.15 Analysis of 
stable samples used only the first stable sample per patient. All 
statistical analyses were carried out using SAS V.9.3 or Graphpad 
Prism V.5.
ReSuLTS
TARdIS population-based genetic study
A flow chart detailing the numbers of samples in both cohorts 
is shown in figure 1, with 1796 patients included in this anal-
ysis; 53% were male, an average age of 64.5 years, a mean FEV1 
of 78% predicted, an FEV1/FVC ratio of 0.58 and a smoking 
history of 41.26 pack years. Table 1 gives details of the cohort at 
baseline, split according to MBL genotype. There were no statis-
tically significant differences in age, gender, FEV1, body mass 
index, comorbidities and smoking status between the groups. 
Mean follow-up time was 5.4 years.
MBL deficiency is associated with reduced exacerbation 
frequency but not mortality in CoPd
During follow-up the rate of exacerbations per patient per year 
was 2.52/year in the MBL sufficient haplotype group and 1.70/
year in patients with MBL deficient haplotypes. In the adjusted 
negative binomial model, MBL deficient haplotypes were asso-
ciated with 23% fewer exacerbations (figure 2) compared with 
MBL sufficient individuals. A significant reduction in exacerba-
tion frequency was observed when comparing MBL deficient 
versus sufficient genotypes, or when comparing patients with 
MBL deficiency with all other groups (incidence rate ratio (IRR) 
0.74, 95% CI 0.56 to 0.98, p=0.04). The effect was greatest for 
severe exacerbations; MBL deficiency reduced the likelihood 
of hospitalisation by 34% (IRR 0.66, 95% CI 0.48 to 0.90, 
p=0.009), although there was no statistically significant differ-
ence on interaction testing (p=0.7), indicating no differential 
effect of MBL deficiency on severe and non-severe exacerba-
tions. Sensitivity analysis showed the reduction in exacerbations 
was driven by a reduction in infective exacerbations requiring 
antibiotics (figure 2). The rates of FEV1 decline were 38.4 mL/
year in patients with MBL deficient haplotypes, 45.1 mL/year in 
those with intermediate haplotypes and 45.0 mL/year in those 
with sufficient haplotypes. In the adjusted linear regression 
model MBL deficiency was not associated with a more rapid 
decline in FEV1 over time (estimate 0.27, SE 0.31, p=0.4). 
Similar results were obtained from the three-level and two-level 
models.
There were 589 deaths from any cause during follow-up 
(32.8% of the cohort). Three hundred and sixty deaths were 
classified as respiratory related, 133 were classified as cardiovas-
cular and 96 were from other causes. The corresponding death 
rates for MBL deficient versus non-deficient groups were 31.3% 
versus 33.1% for all-cause mortality, 17.5% versus 20.5% for 
respiratory mortality and 6.3% versus 7.6% for cardiovascular 
deaths. In the adjusted analysis, MBL deficiency (deficient vs 
non-deficient) was not associated with respiratory (HR 0.83, 
95% CI 0.56 to 1.35, p=0.4), cardiovascular (HR 0.81, 95% CI 
0.44 to 1.48, p=0.5) or all-cause mortalities (HR 0.94, 95% CI 
0.72 to 1.24, p=0.7) (figure 2). Similar results were obtained 
using the three-level model. Intermediate expressing haplotypes 
were not associated with increased exacerbation frequency 
compared with sufficient haplotypes (IRR 0.98, 95% CI 0.82 to 
1.18, p=0.8).
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Figure 2 Risk of exacerbations, cardiovascular hospitalisations and mortality according to mannose binding lectin (MBL)2 genotype. Two models 
were made comparing MBL sufficient, intermediate and deficient genotypes (three-level model) and comparing MBL deficient to non-deficient 
(intermediate and sufficient combined) genotypes (two-level model). A rate ratio <1 indicates a lower risk of exacerbation, hospitalisation or mortality 
with low expressing genotypes. Results are significant at p<0.05 where the 95% CI does not cross a ratio of 1.0.
Chronic obstructive pulmonary disease
Microbiota subcohort study
Based on the finding of less frequent and fewer infective exac-
erbations in patients with MBL deficiency, we recruited two 
subcohorts of patients with TARDIS COPD by MBL genotype 
to compare the microbiota and inflammatory profiles between 
these subcohorts (figure 1, n=141). Thirty-four patients 
were classified as MBL deficient and 107 as MBL non-defi-
cient by genotypes. At baseline, patients with MBL deficient 
and non-deficient genotypes were well matched in terms of 
Medical Research Council (MRC) Dyspnoea Score, quality of 
life (St George's Respiratory Questionnaire), symptoms (COPD 
assessment test), Global Obstructive Lung Disease (GOLD) 
2011 class and per cent predicted FEV1 (table 2).
MBL deficiency is associated with an increased diversity in 
microbiota
Forty-two patients could not provide sputum samples during 
the study; comparisons between sputum producers and the 
whole cohort (online supplementary table E1) indicated 
there was no significant difference in baseline characteristics 
between sputum producers and non-producers. Two hundred 
and ten sputum samples were obtained; 184 sputum samples 
were of sufficient quality and quantity for successful bacterial 
DNA extraction and 16S rRNA gene sequencing. One hundred 
and twenty-six samples passed the subsequent data analysis 
quality control cut-offs; 89 were from patients when clinically 
stable, 16 were start of exacerbation and 21 were end of exac-
erbation samples.
Figure 3A shows one representative stable microbiota from 
each patient, alongside a comparison of the averaged micro-
biota profiles for the MBL deficient versus non-deficient 
populations (figure 3B). α Diversity (a measure of the even-
ness and richness of the microbiota of individual samples) 
was determined by Shannon-Wiener Diversity Index (S-WDI); 
patients with MBL deficiency  had a more diverse lung 
microbiota than patients without MBL deficiency (p=0.008, 
figure 3D) and were less likely to be colonised with Haemoph-
ilus spp (figure 4B, p=0.043). Decreasing α diversity (lower 
S-WDI) was associated with more severe GOLD Score 
(figure 3E, p=0.045), with two clusters of S-WDI being driven 
by the percentage of operational taxonomic units (OTUs) 
identified as Haemophilus spp (figure 3F). The β diversity, a 
measurement of how different individual samples microbiota 
are from each other, of all stable samples is shown in the online 
supplementary figure E1.
haemophilus spp dominance is associated with disease 
severity and increased airway inflammation
The dominant Haemophilus spp in 39.2% of the stable patients, 
identified by a BLASTn search (https:// blast. ncbi. nlm. nih. gov/ 
Blast. cgi) of representative sequences of each Haemophilus 
OTU, was H. influenzae (figure 4A). A cut-off of 40% Haemoph-
ilus spp OTUs (based on figure 3F) was used to stratify patients 
as Haemophilus spp dominant and compared with markers of 
disease severity and exacerbation frequency (figure 4C,D). A 
more severe GOLD Score and more exacerbations per year were 
associated with having >40% Haemophilus spp OTUs (both 
p=0.03).
Lung inflammatory profiles, including IL-1β (previously 
shown to distinguish between infectious and non-infectious 
drivers of inflammation in COPD16), were compared between 
samples with less than or greater than 40% Haemophilus 
spp OTUs. Significantly higher levels of IL-1β (p<0.0001) 
and TNFα (p<0.0001) were observed in sputum samples 
from stable patients with >40% Haemophilus spp OTUs 
(figure 4E,F). Systemic markers of inflammation or sputum 
myeloperoxidase, EN-RAGE or IL-8 were not significantly 
different in patients categorised according to % Haemophilus 
spp OTUs.
group.bmj.com on December 4, 2017 - Published by http://thorax.bmj.com/Downloaded from 
5Dicker AJ, et al. Thorax 2017;0:1–9. doi:10.1136/thoraxjnl-2016-209931
Table 2 Baseline characteristics of the patients with mannose 
binding lectin (MBL) deficiency and patients without MBL deficiency in 
the microbiome subcohort study. GOLD class was calculated based 
on the 2011 guidelines. p Values were calculated through pairwise 
comparisons by T test for parametrical data and Mann-Whitney U test 
for non-parametrical data 
MBL deficient 
genotypes
MBL non-deficient 
genotypes p Value
Demographics and major comorbidities
  N 34 107
  Age, years (SD) 72.8 (±7.3) 70.8 ± (8.2) 0.2
  Age at diagnosis, years (SD) 59.5 (±9.1) 60.2 (±11.9) 0.8
  Male gender (%) 22 (64.7) 67 (62.6) 0.8
  Active smokers (%) 7 (20.6) 21 (19.6) 0.9
  Cigarette smoking by pack 
years (SD)
45.1 (±29.9) 41.7 (±28.9) 0.6
  Body mass index (SD) 28.2 (±5.3) 28.1 (±5.6) 0.9
  Myocardial Infarction (%) 4 (12.1) 12 (11.2) 0.9
  CABG (%) 3 (8.8) 12 (11.2) 0.7
  Angina (%) 6 (18.2) 24 (22.4) 0.6
  Stroke (%) 7 (20.6) 6 (5.6) 0.008
  Diabetes (%) 5 (14.7) 22 (20.6) 0.4
COPD characteristics
  FEV1 per cent predicted (SD) 65.0 (±19.4) 72.1 (±20.7) 0.08
  MRC Dyspnoea Score (SD) 3.0 (±1.5) 2.58 (±1.4) 0.1
  Exacerbations per year (SD) 1.5 (±1.5) 1.9 (±1.9) 0.3
  Blood eosinophils >2% (%) 16 (47.1) 70 (65.4) 0.06
  GOLD Score 0.6*
  A (%) 2 (5.9) 15 (14.0) –
  B (%) 14 (41.2) 38 (35.5) –
  C (%) 2 (5.9) 4 (3.7) –
  D (%) 16 (47.1) 50 (46.7) –
  SGRQ (SD) 47.8 (±23.3) 39.7 (±22.6) 0.07
  On LTOT (%) 0 (0) 5 (4.7) 0.2
Medications
  ICS/LABA (%) 22 (64.7) 62 (57.9) 0.5
  LABA alone (%) 3 (8.8) 13 (12.1) 0.6
  LAMA (%) 19 (55.9) 51 (47.7) 0.4
  Mucolytic (%) 7 (20.6) 10 (9.3) 0.08
  Aspirin (%) 10 (29.4) 27 (25.2) 0.6
  β blocker (%) 5 (14.7) 13 (12.1) 0.7
  Statin (%) 20 (58.8) 56 (52.3) 0.5
  ACE inhibitor (%) 7 (20.6) 30 (28.0) 0.4
  Clopidogrel (%) 3 (8.8) 7 (6.5) 0.7
*indicates Χ2 test across all four GOLD groups. 
CABG, coronary artery bypass graft; GOLD, Global Obstructive Lung Disease; ICS, 
inhaled corticosteroids; LABA, long-acting β agonist; LAMA, long-acting muscarinic 
antagonist; LTOT, long-term oxygen therapy; SGRQ, St George's Respiratory 
Questionnaire. 
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MBL deficiency is associated with reduced airway 
inflammation
Taking one stable sample from each patient, MBL deficiency was 
associated with decreased sputum concentrations of EN-RAGE 
and IL-1β (p=0.046 and p=0.032, respectively, figure 5); there 
were no significant differences with other markers of inflamma-
tion (serum CRP, serum CD40L, serum P-selectin, sputum Il-8 
sputum, sputum TNF-α or sputum myeloperoxidase). MBL 
deficiency in patients with COPD is associated with less airway 
inflammation.
MBL binds haemophilus spp but not P. aeruginosa or 
Streptococcus pneumoniae
Since MBL deficiency was protective against Haemophilus 
dysbiosis but not other potential respiratory pathogens, and 
because MBL binding is required for its effect on phagocytosis, 
we hypothesised that MBL would bind H. influenzae. We inves-
tigated the ability of MBL to bind to respiratory pathogens in 
vitro. We observed that MBL bound to H. influenzae, along with 
Staphylococcus aureus, Burkholderia cenocepacia and Esche-
richia coli but did not bind to P. aeruginosa, or Streptococcus 
pneumoniae (figure 6).
dISCuSSIon
This study demonstrates that MBL deficiency is associated 
with a significantly lower frequency of exacerbations in a 
large cohort of patients with COPD. In the microbiota subco-
hort, MBL deficiency was associated with a more diverse 
microbiota, and in particular, a reduction in Haemophilus 
spp OTUs. Loss of microbiota diversity with dominance of 
Haemophilus spp is associated with more severe disease, 
more frequent exacerbations and greater airway inflamma-
tion. Our finding that MBL deficiency is protective against 
Haemophilus spp infection is consistent with data showing 
that oxidised MBL disrupts MBL oligomer formation and 
inhibits phagocytic clearance of Haemophilus spp in COPD 
alveolar macrophages.12 Impaired phagocytosis of Haemoph-
ilus spp in COPD macrophages has been previously demon-
strated; our data fit with the proposal that MBL has a role 
in inhibiting clearance of bacteria from the airway.13 17 MBL 
deficiency may be beneficial, by removing an inhibitory 
factor preventing bacterial phagocytosis. The 23% reduction 
in exacerbations we observed in the MBL deficient group 
is clinically important, and is equivalent to the reduction 
observed when ICS are added to long-acting β agonists in 
randomised controlled trials.18
Our COPD data contrast to CF and bronchiectasis data, where 
poor outcomes are most strongly associated with P. aeruginosa 
infection. MBL deficiency increases the frequency and severity of 
P. aeruginosa infections in humans and mice, while studies show 
lower mortality in patients infected with H. influenzae compared 
with P. aeruginosa and other bacteria.7 8 19 20 In the largest bron-
chiectasis cohort study, colonisation with H. influenzae was asso-
ciated with a lower frequency of exacerbations compared with 
P. aeruginosa or Veillonella spp colonisation.21 COPD, bron-
chiectasis and CF have differing microbiota and inflammatory 
profiles and very different clinical presentations. Therefore, it is 
plausible MBL deficiency may have different impacts in different 
diseases. Indeed it has been long speculated that the high MBL 
deficiency frequency in the population suggests a balanced effect 
whereby it is harmful under some circumstances but beneficial 
under others.22
The effect in this study appeared to be relatively specific for H. 
influenzae. We found that MBL bound to H. influenzae in vitro, 
but not to other clinically relevant bacteria except S. aureus and 
B. cenocepacia which are pathogens more frequently isolated in 
CF than in COPD. The specificity for H. influenzae in COPD is 
therefore likely to reflect the requirement for oxidised MBL to 
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Figure 3 (A) Stacked bar graphs showing the stable microbiota of individual patients, split according to mannose binding lectin (MBL) genotype. 
Each stacked bar represents one patient when clinically stable; each patient is only represented once, n=17 deficient and n=58 non-deficient samples. 
Individual operational taxonomic units (OTUs) representing less than 0.5% of the total number of OTUs in a sample and not represented in more than 
10 samples were excluded from this figure for clarity. (B) Stacked bar graphs showing the average stable microbiota of patients with MBL deficiency 
and patients without MBL deficiency. Each patient was represented by their first stable sample. (C) Graph showing the average difference in % OTUs 
of patients with MBL deficiency and patients without MBL deficiency. For clarity, only genera with an average change of greater than 0.1% are 
shown. (D) Reduced microbiota α diversity (Shannon-Wiener Diversity Index (S-WDI)) is associated with a MBL non-deficient genotype by Spearman 
correlation. Each patient was represented with their first stable sample. (E) Lower S-WDI was associated with a more severe GOLD Score by Mann-
Whitney test. (F) The relationship between % OTUs identified as Haemophilus spp and S-WDI in stable COPD. Graphs show mean with SE.
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bind in order to inhibit phagocytosis, combined with the high 
prevalence of H. influenzae in patients with COPD.
Previous studies on the impact of MBL deficiency in COPD 
are inconsistent; none have enrolled >300 patients without 
preselection for a subset of patients with COPD, that is, frequent 
exacerbators,23 or had sufficient follow-up time to evaluate 
exacerbation frequency, whereas we analysed the electronic 
medical record data from 1796 patients with COPD with 
an average follow-up of 5.4 years. In the present study, MBL 
deficiency status was not found to have an effect on decline in 
FEV1, mortality or hospital admissions for cardiovascular events. 
The study was not specifically powered for these exploratory 
end points, however, larger studies or longer follow-up will be 
needed to thoroughly investigate these outcomes.
Compared with the human gastrointestinal tract micro-
biota, relatively little is known about the lung microbiota 
both in health and various lung disease states. The majority 
of COPD lung microbiota studies have low patient numbers 
with limited longitudinal sampling, confounded by different 
sample collection techniques, in populations with varying 
disease severity or bacterial colonisation status.2 24–26 In 
comparison, we were able to obtain sputum from a larger 
cohort of patients with COPD. While there are concerns 
that the oral microbiota may contaminate sputum,27 induced 
sputum was chosen due to its less invasive nature (compared 
with bronchoscopy) and the likelihood of obtaining sufficient 
sample for sequencing. Our results, showing a stable micro-
biota dominated by Haemophilus, Veillonella, Prevotella and 
Streptococcus spp, are similar to those obtained by other 
sample collection methods,2 24–26 and from healthy smokers 
and non-smokers.27 Additionally our data indicating a reduc-
tion in α diversity in more severe COPD and with a non-de-
ficient genotype correlate with other studies which have 
compared the lung microbiota of different COPD stages with 
healthy smokers and non-smokers.2 We observed relatively 
few Pseudomonas genera OTUs.2 24–26 Our study was commu-
nity based, examining a patient population with less severe 
COPD than other studies, and may be more representative 
of the wider patient population with COPD since Pseudo-
monas spp are known colonisers in more severe COPD and 
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Figure 4 (A) Graph showing only the Haemophilus spp operational taxonomic units (OTUs) from each sample further identified to species level 
indicating the dominant Haemophilus spp was Haemophilus influenzae; all samples were from stable patients and each patient was only represented 
once. (B) Mean percentage of OTUs identified as Haemophilus spp in patients with mannose binding lectin (MBL) deficiency and patients without 
MBL deficiency. (C) One stable sample per patient classified according to GOLD 2011 Score, colour coded according to whether the sample 
had >40% Haemophilus spp OTUs. (D) The percentage of OTUs identified as Haemophilus spp compared with the number of exacerbations per 
year. (E,F) Sputum IL-1β and TNFα concentrations from stable patients with COPD (one sample per patient) stratified according to percentage of 
Haemophilus spp OTUs in sample. (G) Example of an exacerbation dominated by Haemophilus spp compared with a non-Haemophilus spp dominated 
exacerbation. Statistical analysis of microbiota data was carried out using the non-parametrical Spearman correlation and Mann-Whitney test, where 
appropriate; graphs show mean with SE.
Chronic obstructive pulmonary disease
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Figure 5 (A) Sputum EN-RAGE (S100A12) levels and (B:) IL-1β levels 
from stable patients with COPD grouped according to mannose binding 
lectin (MBL) genotype. Statistical analysis was carried out using the 
non-parametrical Mann-Whitney test.
Figure 6 Binding of lectin pathway components to respiratory 
pathogens. Binding is expressed as a percentage of the positive control 
(acetylated bovine serum albumin for ficolin-2/ficolin-3 and mannan for 
mannose binding lectin (MBL)). Binding assays represent the mean with 
SE of three independent experiments performed in duplicate.
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bronchiectasis.28 29 We observed a clear correlation between 
clinical disease severity and microbiota diversity using S-WDI, 
similar to the reduced lung microbiota diversity shown to be 
associated with more severe COPD in other studies.25
This study is the first to have sufficient statistical power to 
demonstrate correlations between microbiota diversity and 
disease severity or inflammatory profiles, both during clinical 
stability and at exacerbation. In addition, this is the first study 
to show a significant genetic modifier of the lung microbiota, 
although whether this modification is direct (through modula-
tion of host immunity) or indirect (through protecting against 
antibiotic use for example), is unclear. This finding needs to be 
validated, but it is logical to expect that host genetics can influ-
ence the composition of the microbiota.
Proinflammatory IL-1β, one of the most useful discriminators 
of bacterial infection in COPD,16 promotes neutrophil recruit-
ment. Neutrophilic inflammation contributes to COPD progres-
sion, and is poorly responsive to ICS.30 We identified higher 
levels of IL-1β and the RAGE ligand S100A12 (EN-RAGE) 
in sputum from patients without MBL deficiency. Although 
elevated IL-1β may be a reflection of the lower bacterial diver-
sity in individuals without MBL deficiency, it has previously been 
shown that exposure to MBL can promote the increased release 
of IL-1β in response to Gram-negative pathogens like Neisseria 
meningitides or by lipopolysaccharide, suggesting that MBL can 
be directly responsible for increased inflammation, independent 
of its effect as an opsonin.31
Limitations of the Go-TARDIS study include the use of 
primary care diagnosis, hospitalisation records and prescription 
data to identify exacerbations, however, these are widely used 
epidemiological methods. The patient population consisted of 
primarily early COPD with preserved lung function, and hence 
the generalisability of these data to later stage COPD would 
need to be confirmed in other studies. The sample size in the 
microbiota subcohort study was relatively small, reflecting the 
fact that MBL deficiency affects only 10% of the population; 
larger, multinational studies would be valuable. Nevertheless, 
this represents the largest study of the microbiota in COPD to 
date and the largest study of the impact of genetic MBL defi-
ciency in COPD.
In conclusion, we have shown, using a large primary care 
based genetic study and a nested microbiota subcohort study, 
MBL deficiency in COPD is protective against the risk of exac-
erbations and is associated with a more diverse lung microbiota. 
MBL genotype is a modifier of disease phenotype and exacerba-
tion risk in COPD.
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